ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China

Hou, Jinlin*; Ning, Qin*; Duan, Zhongping; Chen, You; Xie, Qing; Wang, Fu-Sheng; Zhang, Lunli; Wu, Shanming; Tang, Hong; Li, Jun; Lin, Feng; Yang, Yongfeng; Gong, Guozhong; Flaherty, John F.; Gaggar, Anuj; Mo, Shuyuan; Cheng, Cong; Camus, Gregory; Chen, Chengwei; Huang, Yan; Jia, Jidong; Zhang, Mingxiang华中科技大学; 南昌大学; 南方医科大学; 上海交通大学; 四川大学; 1
Journal of Clinical and Translational Hepatology2021-5DOI: 10.14218/JCTH.2020.00145
17被引5阅读
引用收藏
分享

摘要

Background and Aims: Tenofovir alafenamide (TAF) has similar efficacy to tenofovir disoproxil fumarate (TDF) but with improved renal and bone safety in chronic hepatitis B patients studied outside of China. We report 3-year results from two phase 3 studies with TAF in China (Clinicaltrials. gov: NCT02836249 and NCT02836236). Methods: Chinese hepatitis B e antigen (HBeAg)-positive and -negative chronic hepatitis B patients with viremia and elevated alanine aminotransferase were randomized 2:1 to TAF or TDF treatment groups and treated in a double-blind fashion for 144 weeks (3 years). Efficacy responses were assessed by individual study while safety was assessed by a pooled analysis. Results: Of the 334 patients (180 HBeAg-positive and 154 HBeAg-negative) randomized and treated, baseline characteristics were similar between groups. The overall mean age was 38 years and 73% were male. The mean HBV DNA was 6.4 log(10) IU/mL. The median alanine aminotransferase was 88 U/L, and 37% had a history of antiviral use. At week 144, the proportion with HBV DNA <29 IU/mL was similar among the two groups, with TAF at 83% vs. TDF at 79%, and TAF at 93% vs. TDF at 92% for the HBeAg-positive and -negative patients, respectively. In each study, higher proportions of TAF than TDF patients showed normalized alanine aminotransferase (via the American Association for the Study of Liver Diseases and the China criteria) and showed loss of HBsAg; meanwhile, the HBeAg seroconversion rates were similar. Treatment was well-tolerated among the TAF patients, who showed a smaller median decline in creatinine clearance (-0.4 vs. -3.2 mL/min; p=0.014) and less percentage change in bone mineral density vs. TDF at hip (-0.95% vs. -1.93%) and spine (+0.35% vs. -1.40%). Conclusions: In chronic hepatitis B patients from China, TAF treatment provided efficacy similar to TDF but with better renal and bone safety at 3 years.

学科与关键词

关键词
Chronic hepatitis B virusAntiviral therapyBone safetyRenal safety
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Journal of Clinical and Translational Hepatology
发表日期
2021-05
卷期
第 9 卷, 第 3 期
页码
324-334
DOI
10.14218/JCTH.2020.00145
期刊收录
NSL
期刊等级
2区
成果收录
SCIE

作者

  • H

    Hou, Jinlin (通讯) (第一作者)

    southern med univ

  • N

    Ning, Qin (通讯)

    huazhong univ sci & technol

查看全部 22 位作者收起作者
  • D

    Duan, Zhongping

    capital med univ

  • C

    Chen, You

    capital med univ

  • X

    Xie, Qing

    shanghai jiao tong univ · shanghai ruijin hosp

  • W

    Wang, Fu-Sheng

  • Z

    Zhang, Lunli

    1 · nanchang univ

  • W

    Wu, Shanming

  • T

    Tang, Hong

    sichuan univ

  • L

    Li, Jun

    1 · nanjing med univ

  • L

    Lin, Feng

  • Y

    Yang, Yongfeng

    2

  • G

    Gong, Guozhong

    2

  • F

    Flaherty, John F.

  • G

    Gaggar, Anuj

  • M

    Mo, Shuyuan

  • C

    Cheng, Cong

  • C

    Camus, Gregory

  • C

    Chen, Chengwei

  • H

    Huang, Yan

  • J

    Jia, Jidong

  • Z

    Zhang, Mingxiang

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417